No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.

Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Ballaouri I, Efstathiadou Z, Kita M, Avramidis A

Clinical endocrinology1 Apr 2009Cited by 7 (Europe PMC)

PMID18625000DOI10.1111/j.1365-2265.2008.03342.xPepBankPUB-18625000

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In osteoporotic women, serum P1NP increased significantly after teriparatide compared with before treatment.
In plain wordsIn women with osteoporosis, the bone marker P1NP increased after teriparatide compared with before treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum P1NP
Study
n = 22
Comparator
Before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · 18 monthsAs given in this study (human).
Source sentences
Summary
Serum P1NP, CTx and total ALP increased significantly after TPTD treatment and decreased at the end of the study in both SR and control groups, with no difference between them.
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS: Twenty-two postmenopausal Caucasian women (aged 65.7 +/- 1.7 years) with established osteoporosis previously treated with TPTD 20 microg daily for 18 months were randomly assigned to receive either SR (SR group, n = 11) or calcium and vitamin D (control group, n = 11).
Summary · context
Blood samples for serum N-terminal propeptide of type 1 collagen (P1NP), C-terminal telopeptide of type 1 collagen (CTx) and total alkaline phosphatase (ALP) were obtained from all women before (pre-TPTD) and after (post-TPTD) TPTD administration, as well as 6 months after SR or calcium/vitamin D ad…
Report a problemFND-1862500001
02HumanNon-randomized trialEfficacy outcome
In osteoporotic women, serum CTx increased significantly after teriparatide compared with before treatment.
In plain wordsIn women with osteoporosis, the bone marker CTx increased after teriparatide compared with before treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum CTx
Study
n = 22
Comparator
Before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · 18 monthsAs given in this study (human).
Source sentences
Summary
Serum P1NP, CTx and total ALP increased significantly after TPTD treatment and decreased at the end of the study in both SR and control groups, with no difference between them.
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS: Twenty-two postmenopausal Caucasian women (aged 65.7 +/- 1.7 years) with established osteoporosis previously treated with TPTD 20 microg daily for 18 months were randomly assigned to receive either SR (SR group, n = 11) or calcium and vitamin D (control group, n = 11).
Summary · context
Blood samples for serum N-terminal propeptide of type 1 collagen (P1NP), C-terminal telopeptide of type 1 collagen (CTx) and total alkaline phosphatase (ALP) were obtained from all women before (pre-TPTD) and after (post-TPTD) TPTD administration, as well as 6 months after SR or calcium/vitamin D ad…
Report a problemFND-1862500002
03HumanNon-randomized trialEfficacy outcome
In osteoporotic women, total ALP increased significantly after teriparatide compared with before treatment.
In plain wordsIn women with osteoporosis, total ALP increased after teriparatide compared with before treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal ALP
Study
n = 22
Comparator
Before teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg daily · 18 monthsAs given in this study (human).
Source sentences
Summary
Serum P1NP, CTx and total ALP increased significantly after TPTD treatment and decreased at the end of the study in both SR and control groups, with no difference between them.
2 context sentences(design, population, supporting numbers)
Summary · context
DESIGN PATIENTS: Twenty-two postmenopausal Caucasian women (aged 65.7 +/- 1.7 years) with established osteoporosis previously treated with TPTD 20 microg daily for 18 months were randomly assigned to receive either SR (SR group, n = 11) or calcium and vitamin D (control group, n = 11).
Summary · context
Blood samples for serum N-terminal propeptide of type 1 collagen (P1NP), C-terminal telopeptide of type 1 collagen (CTx) and total alkaline phosphatase (ALP) were obtained from all women before (pre-TPTD) and after (post-TPTD) TPTD administration, as well as 6 months after SR or calcium/vitamin D ad…
Report a problemFND-1862500003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.